A phase 2/3 registrational clinical trial of AVR-RD-06 in Gaucher disease type 3
Latest Information Update: 24 Jul 2024
At a glance
- Drugs AVR-RD-06 (Primary)
- Indications Gaucher's disease type III
- Focus Registrational; Therapeutic Use
- Sponsors AVROBIO; Tectonic Therapeutic
- 20 Jun 2024 According to a Tectonic Therapeutic media release, AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic.
- 04 Jan 2022 According to an AVROBIO media release, the company expects to initiate this study in 2023.
- 13 Aug 2021 New trial record